Notice of Extraordinary General Meeting of Orexo AB, February 16, 2011

Notice of Extraordinary General Meeting of Orexo AB, February 16, 2011

 

Uppsala, January 11, 2011 - Orexo AB announces notice concerning Orexo's
Extraordinary General Meeting on February 16, 2011, and the complete
proposal from the Board of Directors regarding the adoption of the
performance-based, long-term incentive program 2011/2021 and the
issuance of warrants to subscribe for new shares, and approval of
disposal of the warrants issued under the incentive program.

Attachments:
- Notice of Orexo's Extraordinary General Meeting on February 16, 2011
- Proposal from the Board of Directors regarding the adoption of the
performance-based, long-term incentive program 2011/2021 and the
issuance of warrants to subscribe for new shares, and approval of
disposal of the warrants issued under the incentive program

For more information, please contact:
Robin Wright, EVP and CFO, Orexo AB
Tel: +44 7720 300025
Email: robin.wright@orexo.com (robin.wright@orexo.com)

 

About Orexo
Orexo is a pharmaceutical company focusing on developing treatments for
pain and inflammation. Orexo is developing proprietary products based on
its proven reformulation technologies, targeted at the Specialty
Pharmaceutical market. Orexo intends to commercialise some of these
products itself in one or more major markets. Its development activity
builds on Orexo's core competences in R&D, which have previously
resulted in several successful products, currently out-licensed through
worldwide partnership agreements to larger pharmaceutical companies.
Today, Orexo has four products on the market of which Abstral® is a
leading product for the treatment of breakthrough pain in cancer
patients in most of Europe. Orexo also has three significant
partnerships with major pharmaceutical companies for research and
development programs: discovery stage collaborations with Ortho-McNeil
Janssen and Janssen Pharmaceutica in respiratory inflammation and with
Boehringer Ingelheim for inflammation and pain, both within the
arachidonic acid cascade and a clinical stage development agreement with
Novartis for the treatment of gastrointestinal disorders. Orexo's head
office is located in Uppsala, Sweden. More information can be found at
www.orexo.com (http://www.orexo.com/).

 

Note:
This is information that Orexo AB (publ.) is required to disclose
pursuant to the Swedish Securities Markets Act. The information was
provided for public release on January 11, 2011 at 12:00. CET.